Exelixis (EXEL) resumes trading after a long halt, now down 33.4% AH, after announcing it's...
Exelixis (EXEL) resumes trading after a long halt, now down 33.4% AH, after announcing it's initiating its first phase 3 trial of cabozantinib for patients with a particular type of prostate cancer. Without an agreement with the FDA, the company's not pursuing a special protocol assessment from the agency.
From other sites
at Zacks.com (Mar 18, 2015)
at Zacks.com (Feb 27, 2015)
at Zacks.com (Feb 23, 2015)
at Benzinga.com (Feb 5, 2015)
at CNBC.com (Dec 8, 2014)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs